InvestorsHub Logo
Followers 66
Posts 4898
Boards Moderated 0
Alias Born 06/12/2014

Re: Cherrypoppers post# 47253

Monday, 06/08/2020 12:11:49 PM

Monday, June 08, 2020 12:11:49 PM

Post# of 113766
****Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug****


Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.





A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.



https://drug-dev.com/sunshine-biopharma-looking-to-mimic-roches-billion-dollar-cancer-drug/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News